Novel therapeutic options for relapsed hairy cell leukemia
Authors:
- 4 February 2015
- journal article
- review article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 56 (8) , 2264-2272
Abstract
The majority of patients with hairy cell leukemia (HCL) achieve a response to therapy with cladribine or pentostatin with or without rituximab. However, late relapses can occur. Treatment of relapsed HCL can be difficult due to a poor tolerance to chemotherapy, increased risk of infections and decreased responsiveness to chemotherapy. The identification of BRAFV600E mutations and the role of aberrant MEK kinase and Bruton's tyrosine kinase (BTK) pathways in the pathogenesis of HCL have helped to develop novel targeted therapies for these patients. Currently, the most promising therapeutic strategies for relapsed or refractory HCL include recombinant immunoconjugates targeting CD22 (e.g. moxetumomab pasudotox), BRAF inhibitors such as vemurafenib and B cell receptor signaling kinase inhibitors such as ibrutinib. Furthermore, the VH4-34 molecular variant of classic HCL has been identified to be less responsive to chemotherapy. Herein, we review the results of the ongoing clinical trials and potential future therapies for relapsed/refractory HCL.Keywords
This publication has 79 references indexed in Scilit:
- Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemiaHaematologica, 2013
- Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutationHaematologica, 2013
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell LeukemiaJournal of Clinical Oncology, 2012
- Both variant and IGHV4-34–expressing hairy cell leukemia lack the BRAF V600E mutationBlood, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- BRAFMutations in Hairy-Cell LeukemiaNew England Journal of Medicine, 2011
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature, 2010
- VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapyBlood, 2009
- Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell LeukemiaJournal of Clinical Oncology, 2009